Cogeco Peer 1 Changes Name to Aptum Technologies; Adds New Services to Enhance and Expand Hybrid Cloud Offerings
Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/
Susan Bowen, CEO of Aptum (Photo: Business Wire)
“Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve complex challenges and maximize the potential of their businesses.”
Headquartered in Toronto, Aptum will operate with two focused business units — Data Center and Fiber. The Data Center business will concentrate on enabling multi-cloud services for enterprises. The Fiber business will be Canada’s first independent, neutral-host provider of small cell and 5G infrastructure, and enterprise and wholesale fiber connectivity with an extensive metro fiber network across greater Toronto and Montreal.
With a 20-year heritage helping customers maximize technologies to store, manage, move and secure their critical data, Aptum is one of a select group of companies able to offer true hybrid infrastructure solutions with secure data center, cloud, connectivity and managed services across North and Central America, Europe, the Middle East and Africa.
Aptum is led by an experienced executive team that includes:
- Susan Bowen, Chief Executive Officer
- Shenif Visram, Chief Finance Officer
- Sanjay Sachdev, President and Head of Fiber
- Leighton Plumley, Chief Revenue Officer (Data Center Business Unit)
- Cindy Jordan-Ford, EVP Global Strategic Accounts & Alliances
- Jeremy Pease, Chief Operating Officer
- Scott Davis, Interim Chief Infrastructure Officer
- Paul Dyck, Vice President, Human Resources
Concurrent with the rebranding, Aptum has launched two new offerings that expand and enhance its customers’ hybrid cloud options:
- Managed Amazon Web Services (AWS) – reinforcing Aptum’s commitment to multi-cloud this new suite of AWS services complements Aptum’s existing Managed Azure and Managed Private Cloud offerings. Managed AWS services include consultation; architecture/design; solution build and configuration; migration; project management; ongoing service management and optimization; and 24/7 expert support. Managed AWS is available in Canada, the U.S. and the U.K.
- New Cloud Connect Availability – expansion of Cloud Connect, which offers a direct, dedicated and secure connection to cloud services. Cloud Connect is now available for AWS Direct Connect, Google Cloud Platform, ServiceNow, Salesforce, SAP and Oracle in addition to Microsoft ExpressRoute. The Cloud Connect expansion is available in all regions.
“The addition of these new cloud services is a perfect example of how Aptum is continually evolving to meet our customers’ changing needs,” Bowen said. “Every business has unique considerations, constraints and objectives that will be met by different solutions. Helping customers determine the correct platform for their unique requirements and then providing expert implementation is why businesses turn to Aptum.”
“As a rapidly growing AI products company, Element AI needed a true partner that could help us focus on our business growth rather than worrying about our data center infrastructure. For the past two years, Cogeco Peer 1 has consistently delivered,” said Ludwig Gamache, IT Director, Element AI. “Our requirements are different from most companies because of the compute-intensive nature of machine learning and AI algorithms – which generate more heat to dissipate and higher power demands than average customers. Element AI is now 35 times bigger than when we launched in 2016, and Cogeco Peer 1 has been able to adapt to solve our unique challenges. We look forward to continuing to evolve our IT infrastructure with Aptum as we grow."
Resources:
- Blog post: https://aptum.com/blog/welcome-to-aptum
- More about the executive team: https://aptum.com/company/leadership-team/
- Additional assets: Logo and executive headshots
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Connectivity solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America and Europe. In Canada, through its Fiber business, Aptum is the first neutral host provider of turnkey small cell connectivity, augmenting an extensive metro network across Toronto and Montreal. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005121/en/
Contact information
Cindy Watson/Mike Martin
StrategicAmpersand
AptumPR@stratamp.com
416-961-5595
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom